ORIGINAL ARTICLE



Virtual Tai Chi program for patients with irritable bowel syndrome with constipation: Proof-of-concept feasibility trial

Kyle Staller^{1,2} Mary Paz³ Ramel Rones⁴ Eric A. Macklin⁵ Isabelle Garcia-Fischer^{1,2} | Helen Burton Murray^{1,2} | Braden Kuo^{1,2}

¹Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston. Massachusetts, USA

²Center for Neurointestinal Health, Massachusetts General Hospital, Boston, Massachusetts, USA

³Institute of Health Professions, Massachusetts General Hospital, Charlestown, Massachusetts, USA

⁴Mind Body Consultant, Tufts Medical Center, Mass General Hospital, Dana Farber Cancer Institute, Boston, Massachusetts, USA

⁵Biostatistics Center, Massachusetts General Hospital and Harvard Medical School Boston, Boston, Massachusetts, USA

Correspondence

Kyle Staller, Division of Gastroenterology, Massachusetts General Hospital, 165 Cambridge Street, Boston, MA 02114,

Email: kstaller@mgh.harvard.edu

Funding information

National Institute of Diabetes and Digestive and Kidney Diseases

Abstract

Background: Satisfaction with current treatment options for irritable bowel syndrome with constipation (IBS-C) is low, with many patients turning to complementary treatments. Tai Chi is a mind-body medicine practice with proven efficacy in other functional disorders. As a proof-of-concept, we tested the feasibility and preliminary clinical outcomes associated with a Tai Chi program designed for IBS-C.

Methods: A total of 27 IBS-C patients participated in a single-arm trial of 8 sessions of Tai Chi delivered weekly over 7 weeks via live videoconferencing in group format. Clinical improvement was assessed via change in IBS Symptom Severity Score (IBS-SSS) from baseline to 4weeks posttreatment (week 11) with secondary outcomes exploring symptom ratings, IBS-related quality of life (IBS-QOL), GI-specific anxiety, abdominal distention, and psychological factors.

Key Results: Despite substantial dropout (n = 7; 26%), the treatment protocol had moderate to excellent feasibility for other criteria. Treatment satisfaction was excellent. Exit interviews confirmed high satisfaction with the program among completers, but a high burden of data collection was noted. One participant experienced an adverse event (mild, exacerbation of sciatica). There was a significant improvement in intra-individual IBS-SSS between baseline and posttreatment (average change -66.5, 95% CI –118.6 to –14.3, p = 0.01). Secondary outcomes were notable for improvements in other IBS symptom scoring measures, IBS-QOL, measured abdominal diameter, and leg strength.

Conclusions and Inferences: Our data provide preliminary evidence of the feasibility of a Tai Chi intervention for IBS-C, show promise for improving outcomes, and identify more streamlined data collection as an area for further program improvement.

KEYWORDS

clinical trial, complementary therapies, functional colonic diseases, Tai Ji

| INTRODUCTION

Irritable bowel syndrome (IBS) is a chronic and common condition with a global prevalence of more than 11% and significant effects on sufferers' quality of life. Despite the availability of both over-the-counter and prescription options for treatment, satisfaction with current treatment options remains low. In irritable bowel syndrome with constipation (IBS-C), only 25% of individuals surveyed were satisfied with available over-the-counter and prescription agents.² With treatment dissatisfaction so prevalent, between

30% and 50% of patients with chronic gastrointestinal (GI) conditions turn to complementary and alternative medicine (CAM) treatments for their symptoms.³ In fact, younger women and those with poor treatment satisfaction are independent predictors of CAM use, such that there is a striking overlap with the demographics of the IBS population, who may see these treatments as safer and more natural than pharmacotherapeutic options.⁴

Tai Chi is an ancient mind-body medicine practice originating in China that integrates physical elements with psychosocial, spiritual, and behavioral components. Meditation is combined with deep breathing and slow, graceful movements to move vital energy (*qi*) throughout the body. Tai Chi has demonstrated benefit in randomized trials for fibromyalgia, a condition with a similar demographic and pathophysiologic overlap with IBS. In both cases, chronic pain with central sensitization and psychosocial factors play an important role in disease presentation and quality of life and are hypothesized mechanistic targets in Tai Chi. Moreover, Tai Chi appears to improve overall psychological well-being, specifically reducing stress, general anxiety, and depression—all modulating factors in IBS. 10

Tai Chi may also be particularly acceptable to patients with IBS, a population seeking out alternative treatments for their symptoms. Because exercise already has an established place in the IBS treatment paradigm, ^{11,12} the integrative use of exercise and meditation techniques used in Tai Chi may be viewed as particularly credible to both providers and patients with IBS. In addition, patients seeking CAM alternatives for IBS symptoms seem to be most bothered by abdominal pain and bloating, ⁴ symptoms where some IBS therapies may be less satisfactory. Given that patients with IBS-C have disproportionate abdominal pain, bloating, and life interference than those with IBS with diarrhea (IBS-D), ¹³ patients with IBS-C may be a prime candidate population for Tai Chi with its integration of both mind (psychological) and body (physical).

We developed a novel Tai Chi program designed to meet the specific needs of patients suffering from IBS-C and tested its feasibility and preliminary outcomes using a nonrandomized, open proof-ofconcept design. Our Tai Chi Program differed from traditional Tai Chi programs by its focus on the internal organs, with self-massage specifically focused on the abdominal muscles and viscera. Additionally, the IBS-C Tai Chi program adapted 10 movements from both the Yang and Chen Tai Chi styles that combined rotations to target massage to the digestive tract. We analyzed the study with the ORBIT model for behavioral interventions in chronic disease¹⁴ in mindspecifically determining feasibility of the intervention in preparation for an efficacy trial. The primary objectives were to evaluate feasibility and engagement in this novel mind-body treatment and evaluate posttreatment changes in IBS symptom severity. We also explored factors that may contribute to therapeutic benefit as well as underlying mechanisms of change. We hypothesized that virtual Tai Chi sessions would be an acceptable and feasible means of treating IBS-C with associated markers of symptom improvement. We hoped this study would set the stage for a future fully powered RCT to test the efficacy of our intervention.

Key Points

Satisfaction with current treatment options for irritable bowel syndrome with constipation (IBS-C) is low, with many patients turning to complementary treatments. We tested the feasibility and clinical outcomes associated with a Tai Chi program designed for IBS-C. We found that Tai Chi had moderate to excellent feasibility overall with excellent treatment satisfaction and significant improvement in symptom severity. Our data provide preliminary evidence of the feasibility of a Tai Chi intervention for IBS-C and show promise for improving outcomes.

2 | METHODS

2.1 | Participants

We conducted the trial from July 20, 2020 to April 27, 2021 at Massachusetts General Hospital (MGH), a tertiary care center in Boston. Inclusion criteria included: (1) aged 18-70 years, (2) Rome IV criteria for IBS-C, (3) continued IBS-C throughout a 2-week run-in period, and (4) willingness to complete the program and study assessments. Exclusion criteria included: (1) inability to stand without assistance for 20 min, (2) current opioid use, (3) BMI>35 kg/m², (4) severe osteoarthritis, (5) severe abdominal pain (measured as a "4" on a 0-4 Visual Analog Scale [VAS]) at screening, (6) severe constipation (defined as <1 bowel movement/week without laxatives), and (7) concurrent inflammatory bowel disease or celiac disease diagnosis. We recruited participants through referrals from the GI clinic at MGH, through a hospital-based study recruitment website, and using a Facebook advertisement. A trained research coordinator (MP) conducted phone screens followed by a virtual appointment with one of the investigators (KS or BK) for confirmation of Rome IV IBS-C diagnosis, virtual exam using videoconferencing technology, and adherence to inclusion and exclusion criteria.

2.2 | Procedures

This study was a single-site, open-label intervention study evaluating the effects of Tai Chi among patients with IBS-C according to the Rome IV criteria. The study was approved by the Institutional Review Board of MGH (IRB#2019P000361) and registered with Clini calTrials.gov (NCT04132804). All participants signed informed consent. Participants were allowed to continue all medications, including laxatives, prokinetics, and antidepressants/neuromodulators as long as the doses were stable in the preceding 3 months. Similarly, participants were asked to avoid any major lifestyle changes including starting a new diet or changing their exercise pattern. The study consisted of three periods: run-in, treatment, and posttreatment follow- up. After phone screening, patients met virtually with investigators for

further confirmation of eligibility and consent. Eligible participants enrolled in a two-week run-in period during which they needed to continue to meet Rome IV criteria for IBS-C and complete 80% of daily symptom diaries. Participants completed a daily stool diary to ensure they met criteria for IBS-C, a daily GeoPain diary (a mobile phone application that allows participants to enter the precise location and severity of their pain, along with alleviating and exacerbating factors) as well as complete a daily VAS pain scale (see "Assessments" below). The study schema is presented in Figure S1. Surveys were completed online using REDCap, a secure web platform for building and managing online databases and surveys.

2.2.1 | Tai Chi intervention

Participants meeting final eligibility criteria during the two-week run-in period started eight weekly, one-hour group-based Tai Chi lessons. Lessons were led by a Tai Chi master (RR) with specific experience with delivering other group-based protocols for other health conditions. Lessons occurred on Days 0, 7, 14, 21, 28, 35, 42, and 49. As this study ran during the COVID-19 pandemic, lessons were administered virtually using a secure Zoom platform (Zoom Video Communications, Inc., San Jose, CA), a collaborative, cloud-based videoconferencing service offering online meetings. Virtual lessons were also thought to improve the scalability and practicality for future, larger treatment trials.

Classes were limited to 10 participants per session, and participants were asked to keep their cameras on so that the instructor could monitor their form and ensure adherence to the protocol. Lessons were conducted in three groups with Group 1 containing 10 enrolled participants and running from August 18, 2020 to September 30, 2020, Group 2 containing 14 enrolled participants and running from November 27, 2020 to December 08, 2020, and Group 3 containing 7 enrolled participants from February 09, 2021 to March 30, 2021. Participants earned \$150 for completion of the study in its entirety (if they completed 7/8 Tai Chi classes and 80% of the diaries).

In the first session, the instructor explained the theory behind Tai Chi and its procedures and provided participants with emailed materials on its principles and techniques. In subsequent sessions, participants practiced 10 forms from the classic Yang style of Tai Chi with self-massage, meditation, and visualization tailored to IBS-C under his instruction (see Appendix for Tai Chi protocol). Each session included a warm-up and self-massage to the abdominal area with a focus on the digestive tract, followed by a review of principles, movements, breathing techniques, and relaxation in Tai Chi. The Tai Chi protocol was partially adapted from those used in previous fibromyalgia studies^{6,8} with significant modification to suit IBS-C patients. In order to target abdominal symptoms, participants were instructed on various meditations and visualizations with a strong focus on relaxing the abdominal and lower back area as well as the internal organs (i.e., participants were instructed in deep breathing with gentle movements of the abdominal wall and back muscles

while visualizing a healing energy ball two inches below the navel). Throughout the intervention period, participants were instructed to practice Tai Chi at home for at least 20 min each day and keep track of practice in their daily diaries. At the end of the 8-week intervention, participants were encouraged to maintain their Tai Chi practice, using printed and digital resources.

2.3 | Measures

2.3.1 | Feasibility measures

Feasibility measures were determined to be consistent with the guidelines for intervention development.¹⁴ We assessed the following measures:

- Feasibility of recruitment: This was assessed as the proportion of potential participants successfully contacted who agreed to participate. We considered a proportion ≥70% good and ≥80% excellent.
- Program acceptability: This was assessed as the proportion of participants who started treatment who attended at least 7 out of the 8 Tai Chi sessions. We considered a proportion ≥70% good and ≥80% excellent.
- Feasibility of quantitative measures: This was assessed as the proportion of participants who started treatment who completed at least 80% of their daily diary entries. We considered a proportion ≥70% good and ≥80% excellent.
- 4. Adherence to home practice: This was assessed as the proportion of participants who started treatment who practiced Tai Chi at home at least 80% of days during the treatment period. We considered a proportion ≥70% good and ≥80% excellent.
- 5. Program satisfaction: This was assessed as the proportion of participants who completed follow-up who rated their treatment satisfaction ("How satisfied were you with your treatment?," 5-point (1–5) scale upper anchor "very satisfied" and lower anchor "very dissatisfied") and likelihood of continuing treatment satisfaction ("How much do you agree with the following statement: I will continue practicing Tai Chi after the end of the trial?," 5-point (1–5) scale upper anchor "strongly agree" and lower anchor "strongly disagree"). We considered a proportion ≥70% rating 4s/5s good and ≥80% excellent.
- 6. Instructor assessment of Tai Chi mastery: This was assessed as the proportion of participants who completed all sessions who were rated by the instructor ("Did the student master the Tai Chi?," 6-point [0-5] scale upper anchor "most mastered"). We considered a proportion ≥70% rating 4s/5s good and ≥80% excellent.
- 7. Instructor assessment of participant enthusiasm: This was assessed as the proportion of participants who completed all sessions who were rated by the instructor ("How enthusiastic or motivated was the student?," 6-point [0–5] scale upper anchor "very enthusiastic/motivated"). We considered a proportion ≥70% rating 4s/5s good and ≥80% excellent.

8. Program safety: This was assessed as the proportion of participants who started treatment who self-reported no treatment-related adverse events. Participants were instructed to contact study personnel if they experienced worsening symptoms, including 5 consecutive days without a bowel movement specifically. Outside of bowel movement frequency, specific adverse events were not elicited unless reported by subjects. Safety was considered excellent if there were no treatment-related adverse events and good if there were minimal to mild adverse events linked to program participation, which occurred in no more than 10% of participants.

2.3.2 | Quantitative measures

The primary quantitative outcome was changed in the IBS Symptom Severity Scale (IBS-SSS)¹⁶ from pretreatment (before the first treatment session) to follow-up (4 weeks after the last treatment session). The IBS-SSS contains five questions: the severity of abdominal pain, the frequency of abdominal pain, the severity of abdominal distention, dissatisfaction with bowel habits, and interference with quality of life. Questions addressing severity of pain and distention, dissatisfaction, and interference are each collected using a VAS with four or five anchors. Frequency of abdominal pain is collected as the number of days over the previous 10 that the individual experienced abdominal pain. Each of the five questions is scored from 0 to 100 and summed for a total score from 0 to 500, with higher scores indicative of worsening symptom severity. A score decrease of ≥50 has been shown to indicate clinically significant improvement in clinical symptoms.¹⁷

Secondary outcomes included the Gastrointestinal Symptom Rating Scale-IBS version (GSRS-IBS), an IBS symptom severity scale with 5 symptom clusters scored from 1 to 7 with 7 representing more severe discomfort¹⁸; IBS Quality of Life Scale (IBS-QoL), range from 0 to 100 with higher scores indicating poorer quality of life¹⁹; Visceral Sensitivity Index (VSI), range from 0 to 75 with higher scores indicating more severe GI-specific anxiety²⁰; irritable bowel syndrome-behavioral responses questionnaire (IBS-BRQ), range from 26 to 182 with higher scores indicating greater IBS avoidance and control behaviors (e.g., avoidance of or hypervigilance around social eating)²¹; Fear of Food Questionnaire, range from 0 to 90, with higher scores indicating greater food fears²²; and the Hospital Anxiety and Depression Scale (HADS), with anxiety and depression subscales that range from 0 to 21, and subscale scores ≥8 suggestive of anxiety or depression.²³ All scales were collected at screening, pretreatment, at session 4, immediately after completing the last Tai Chi session, and at 4 weeks posttreatment.

Participants also completed daily VAS scales evaluating abdominal pain (4-point scale), abdominal discomfort, bloating, and constipation severity (10-point scale for abdominal bloating, discomfort, and constipation severity; higher scores indicating more severe symptoms).

Because of the predominance of abdominal distention as a primary complaint in the IBS-C population, we measured

anthropomorphic measures at the first, middle, and last session as well as 4 weeks posttreatment including weight (with calculation of body mass index [BMI]) and abdominal circumference. Abdominal circumference, self-reported by participants due to the virtual nature of the study, was measured at the point just below the belly button (using a flexible tape measure mailed to each participant on enrollment) at 3:00 PM each day. Leg strength was assessed throughout the study as in previous interventions²⁴ as an alternative surrogate for Tai Chi mastery in that leg strength represents confidence, security, and self-esteem, as a means of "awakening healing from within." Leg strength was assessed by patient report by having participants sit up against a wall, knees bent at a 110-degree angle with no support for as long as possible to measure progression over the course of the treatment.

Participants recorded both complete spontaneous bowel movements (CSBMs) and spontaneous bowel movements (SBMs) in daily diaries throughout the run-in, study period, and 4-week follow-up period. Data from the GeoPain diary will be analyzed and reported in a separate publication due to the novel nature of this instrument.

We conducted semi-structured exit interviews by phone after the final posttreatment visit or at study withdrawal for all participants whom we were able to contact. Interviews were audiorecorded while responses were simultaneously entered into an online, secure database. Key themes were later extracted from interview findings using a form of rapid analysis.

2.4 | Statistical analysis

Baseline patient characteristics were summarized using descriptive statistics. Feasibility markers were evaluated based on the proportion of participants who achieved each benchmark, as detailed earlier in the Feasibility Measures. The primary quantitative endpoint, IBS-SSS, was analyzed in a mixed model repeated measures analysis with unstructured within-person covariance among the repeated assessments. Adjusted means for IBS-SSS at each study timepoint change in IBS-SSS from pretreatment (baseline, 1st class) to post-treatment follow-up (11 weeks, 4 weeks after study completion) were estimated by linear contrasts. A group-level random effect was considered, but zero variance was estimated. The mixed model accounted for missing data when participants withdraw. Similar analyses were used for our secondary outcome measures.

3 | RESULTS

3.1 | Participant characteristics

A total of 130 patients were referred and completed a phone screen for eligibility with 38 patients agreeing to undergo screening and 31 IBS-C patients completing the virtual screening visit and run-in (Figure 1). Patient characteristics are summarized in Table 1. The sample was predominantly middle-aged (mean age 41 years), female

(25/27, 93%), and white (22/27, 82%), with higher levels of comorbid general anxiety (78% scored above the cutoff for anxiety). Six participants (22%) reported chronic musculoskeletal conditions (e.g., chronic back pain, arthritis, or fibromyalgia). The majority of participants (23/27, 85%) had used laxatives to treat their IBS-C symptoms, but 17/27 (63%) had never seen a provider for their symptoms. Recruitment was relatively evenly distributed across clinical (GI clinic) and nonclinical sources (advertising). At baseline, patient symptom severity was moderate (IBS-SSS score 236 ± 21.9) and mean IBS-QOL score was 91 ± 6 . Participants rated their abdominal pain as a 1.8 on a 0-4 VAS, while bloating was the most severe symptom (over constipation and abdominal discomfort) by VAS (5 on a 0-10 scale).

3.2 | Feasibility and acceptability markers

Four participants withdrew during the run-in period, one due to lack of a bowel movement for 8 days not responding to rescue treatment requiring an ED visit and three due to the cumbersome nature of the symptom diaries, questionnaires, electronic recording, and class attendance as the primary reason for withdrawal (see qualitative data below). Seven participants (26%) did not complete the study after initiating treatment. One subject experienced a treatment-related adverse event, exacerbation of sciatica, that required physical therapy, but the event did not lead the subject to drop out of the study. Sixty-seven percent (18/27) of participants attended ≥7 of 8 classes (moderate program acceptability) and 56% (15/27) completed ≥80%

of the daily diaries, while patient adherence to other quantitative measures and home practice was less robust (Table 2). Feasibility of recruitment was excellent, with 31 out of 38 (82%) meeting study criteria agreeing to participate. Satisfaction among participants who completed follow-up was excellent.

3.3 | Quantitative outcomes

Data for each quantitative outcome are presented in Table 3.

3.3.1 | Primary outcome: Change in IBS symptom severity score

Participants showed significant improvements from pretreatment to follow-up (adjusted mean difference of -66.5, 95% CI -118.6 to -14.3, p = 0.01) (Figure 2). Forty-one (11/27) percent of participants exceeded the 50-point improvement considered clinically significant for the IBS-SSS. ¹⁷ Change in IBS-SSS was similar among the subset who completed follow-up.

3.3.2 | Secondary quantitative outcomes: Other patient-reported outcomes

Participants experienced significant improvements in quality of life (IBS-QOL) and several GSRS-assessed symptoms (constipation,




TABLE 1 Demographics and baseline characteristics^a

	Tai Chi intervention			
Characteristic	group (N = 27)			
Demographics				
Age, mean (SD), years	41.1 (16.2)			
Female	25 (92.6)			
BMI, mean (SD), kg/m ²	23.5 (3.6)			
Race				
American Indian/Alaska Native	0 (0)			
Asian	4 (14.8)			
Native Hawaiian/Pacific Islander	3 (11.1)			
Black/African Americana	1 (3.7)			
White	22 (81.5)			
More than one race	0 (0)			
Hispanic/Latinx	2 (7.4)			
Psychological comorbidities				
HADS anxiety, mean (SD)	9.7 (3.7)			
HADS depression, mean (SD)	5.4 (3.4)			
HADS total, mean (SD)	15.1 (6.2)			
Concomitant medications				
Laxatives	23 (85.2)			
Miralax	6 (22.2)			
Dulcolax	6 (22.2)			
Sennosides	2 (7.4)			
Enema	3 (11.1)			
Linaclotide	3 (11.1)			
Magnesium	3 (11.1)			
Neuromodulators	9 (33.3)			
SSRIs	5 (18.5)			
SNRIs	1 (3.7)			
Tricyclic antidepressant	2 (7.4)			
Gabapentin	1 (3.7)			
Seen GI provider for symptoms	10 (37.0)			
Referral source				
MGH GI clinic	12 (44.4)			
Recruitment website	12 (44.4)			
Facebook ad	1 (3.7)			
Word of mouth	2 (7.4)			

Abbreviations: SD, standard deviation; BMI, body mass index; HADS, hospital anxiety and depression score; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin-norepinephrine reuptake inhibitor; MGH, Massachusetts General Hospital.

^aData are shown as number (percentage) unless otherwise noted. Percentages are rounded.

bloating, and satiety). Pre- to posttreatment VAS scales significantly improved for abdominal discomfort and bloating. Changes in constipation and abdominal pain were not significant. There were significant improvements in the Fear of Food Questionnaire and most subscales. Anxiety and depression (by HADS) and GI-specific anxiety (by VSI) did not improve significantly from pre- to posttreatment (Figure 3).

TABLE 2 Feasibility and acceptability benchmarks

Outcome	Tai Chi intervention group
Feasibility of recruitment	31/38 (82%) screened and eligible participants agreed to participate (excellent)
Feasibility of study completion	20/27 (74%) participants successfully completed the entire study (<i>moderate</i>)
Participant satisfaction	19/20 participants (95%) rating 4s/5s (excellent) on treatment satisfaction and 19/20 (95%) participants rating 4s/5s out of 5 (scale 1–5) on likelihood of continuing Tai Chi (excellent)
Acceptability of treatment	18/27 participants (67%) attended ≥7 out of 8 Tai Chi lessons (<i>moderate</i>)
Adherence to daily diary	15/27 participants (56%) completed ≥80% of the daily diaries (<i>moderate</i>)
Adherence to Tai Chi practice	11/20 participants (55%) practiced Tai Chi ≥80% of days during the treatment period (moderate)
Instructor assessment of Tai Chi mastery	14/20 participants (70%) were rated as 4s/5s out of 5 (scale 0–5) (<i>good</i>)
Instructor assessment of Tai Chi enthusiasm	19/20 participants (95%) achieved an enthusiasm level of 4s/5s out of 5 (scale 0–5)(excellent)
Treatment- related adverse events	1/20 participants (5.0%) had an adverse event (good)

3.3.3 | Secondary quantitative outcomes: Physical measurements

Peak abdominal distention significantly decreased by 6.2 cm from pre- to posttreatment, which was accompanied by an increase in measured leg strength. Average weight and BMI dropped over the course of the study, but the magnitude of the decrease was limited.

3.3.4 | Secondary quantitative outcomes: Bowel movement frequency

Participants reported 2.2 ± 3.2 CSBMs at baseline which increased marginally to 2.8 ± 2.9 at week 8, whereas SBMs decreased from 8.5 ± 5.8 at baseline to 8.0 ± 4.3 at week 8. Patients did not complete daily CSBM/SBM diaries after completing the class.

3.4 | Exit interviews

Three main themes emerged across semi-structured exit interviews across 14 participants, including 5 who withdrew from the study or during run-in.

TABLE 3 Primary and secondary outcome data over time

				4-week		
	Baseline	Midtreatment	Posttreatment	follow-up	Estimated	
Measure	(n = 27)	(n = 21)	(n = 20)	(n = 20)	change ^a	p-value ^a
IBS-SSS (1° measure)	236 (21.9)	193 (25.4)	186 (22.0)	169 (21.3)	-66.5 (26.2)	0.01
Secondary IBS survey measures						
IBS-QOL	90.6 (6.3)	87.0 (6.9)	81.0 (6.5)	73.1 (5.7)	-17.5 (3.6)	<0.0001
Visceral sensitivity index	42.1 (3.5)	42.4 (4.2)	36.2 (4.0)	37.3 (4.3)	-4.9 (4.2)	0.25
IBS-BRQ score	92.6 (5.6)		82.2 (5.8)	82.8 (5.6)	-9.8 (5.0)	0.05
GSRS score						
Constipation	4.0 (0.22)		3.7 (0.31)	3.3 (0.26)	-0.73 (0.31)	0.02
Bloating	4.1 (0.28)		3.5 (0.29)	3.2 (0.30)	-0.85 (0.33)	0.01
Pain	3.8 (0.23)		3.3 (0.24)	3.4 (0.24)	-0.44 (0.30)	0.16
Diarrhea	2.4 (0.25)		2.2 (0.27)	1.9 (0.24)	-0.51 (0.30)	0.10
Satiety	3.9 (0.31)		3.2 (0.32)	2.9 (0.29)	-1.0 (0.39)	0.01
VAS scales ^b						
Abdominal discomfort	4.3 (0.46)	3.5 (0.65)	3.2 (0.56)	2.5 (0.50)	-1.8 (0.63)	0.005
Constipation	3.4 (0.52)	3.0 (0.60)	3.3 (0.66)	2.3 (0.44)	-1.1 (0.59)	0.07
Bloating	5.0 (0.46)	3.9 (0.60)	4.1 (0.61)	3.2 (0.67)	-1.8 (0.60)	0.004
Abdominal pain ^c	1.8 (0.16)	1.5 (0.26)	1.2 (0.22)	1.5 (0.14)	-0.32 (0.20)	0.12
Physical measures						
Weight, kg	66.3 (2.8)	65.9 (2.7)	65.6 (2.8)	65.7 (2.8)	-0.65 (0.30)	0.03
BMI, kg/m ²	23.5 (0.72)	23.4 (0.70)	23.3 (0.71)	23.3 (0.72)	-0.20 (0.11)	0.06
Waist circumference, cm	85.4 (2.2)	82.8 (2.5)	81.9 (2.4)	79.3 (2.2)	-6.2 (1.9)	0.002
Leg strength, min	102 (17)	135 (20.1)	155 (22.5)	144 (23.9)	+38.8 (18.7)	0.04
Fear of food questionnaire score	44.3 (4.1)		39.7 (4.5)	35.6 (4.3)	-8.7 (3.2)	0.008
GI fears	3.2 (0.23)		2.9 (0.27)	2.6 (0.26)	-0.61 (0.24)	0.01
Food fears	3.1 (0.24)		2.5 (0.29)	2.3 (0.32)	-0.76 (0.25)	0.003
Food avoidance	3.1 (0.27)		3.2 (0.27)	3.0 (0.30)	-0.18 (0.26)	0.48
Social impairment	1.4 (0.27)		1.1 (0.22)	0.67 (0.14)	-0.72 (0.22)	0.002
Distress/loss of pleasure	2.4 (0.34)		2.3 (0.32)	2.3 (0.32)	-0.16 (0.28)	0.56
HADS score						
Anxiety score	9.7 (0.73)	9.1 (0.95)	9.1 (1.01)	8.9 (1.1)	-0.79 (0.87)	0.37
Depression score	5.4 (0.6)	5.0 (0.71)	5.0 (0.76)	4.8 (0.76)	-0.59 (0.46)	0.21

Note: Pretreatment: at first Tai Chi class (Day 0); Midtreatment: 4 weeks into Tai Chi program (Day 28); Posttreatment: after last Tai Chi class (Day 49); Follow-up: 4 weeks after completing program (Day 77).

Abbreviations: GSRS-IBS, Gastrointestinal Symptom Rating Scale—IBS version; HADS, Hospital Anxiety and Depression Scale; IBS-SSS, IBS Symptom Severity Scale; IBS-QOL, IBS Quality of Life Scale; VAS, Visual Analog Scale.

3.4.1 | Theme 1: Perceptions of program benefits

Participants spoke highly of the program skills and how practicing them provided hope for the power of the mind-gut connection. Participants

identified abdominal massage, meditation, and breathing as specific beneficial aspects of the intervention. However, one participant felt that the program was not as effective because it attempted to target a mixed audience (with respect to level of physical ability).

^aData are shown as estimated means (SE) from mixed model repeated measures analysis with unstructured covariance among the repeated measures to determine adjusted means for a measure at each study timepoint and whether there was a significant difference in measure over time from pretreatment to 4-week follow up Day 77.

^bParticipants were asked to rate the severity of their constipation, bloating, or abdominal discomfort on a visual analog scale (VAS) scale from 0 to 10, 0 being no symptom and 10 being the worst severity.

The VAS asked participants to rate their average level of abdominal pain in the past week, 0 being the least amount of pain and 4 being the most amount of pain.




FIGURE 2 IBS Symptom Severity Score (IBS-SSS) change over time; mean group change in bold

3.4.2 | Theme 2: Online format

Opinion on the use of the video-based format was split. Multiple participants cited the ease of the video-based format, which offered flexibility and greater individual participation. Others cited a desire for in-person treatment to ensure proper positioning and movement and inability to follow along in the video-based format. One participant preferred more interaction with other participants during sessions.

3.4.3 | Theme 3: Process and barriers

All three participants who withdrew from the study during run-in or during the study itself noted difficulties with the data collection process, which they noted was difficult to keep up with and not user friendly. Similarly, some participants found the data entry too time consuming. One participant felt that the daily diary reporting helped identify symptoms more clearly. Three participants (including one who withdrew from the study) felt that the program required a large amount of memorization, which took away from the meditative aspect of the practice.

4 | DISCUSSION

In this proof-of-concept feasibility study of Tai Chi for the treatment of IBS-C, we demonstrated overall feasibility of a virtually delivered platform for this mind-body intervention. We also demonstrated improvements in multiple IBS-C patient-reported parameters with significant improvement in symptom severity during the study. This study adapted a virtual, group-based Tai Chi program for the specific needs of patients with IBS-C.

These findings, combined with previous randomized studies on the effect of Tai Chi in fibromyalgia, ^{6,8} suggest that using a virtual Tai Chi program for IBS-C may be both feasible and effective for a biopsychosocial illness such as IBS-C. Consistent with the ORBIT feasibility model, however, our preliminary outcome

data should be interpreted with caution. Specifically, the trial was neither designed nor powered for efficacy and lacked a control arm. Nevertheless, these results demonstrate proof-of-concept and motivate evaluation of the intervention in a larger, future trial. The other issue with relevance to any future trial designs is the significant attrition rate seen in this study. Although most attrition occurred in the early phases of the trial, all withdrawing participants—regardless of timing—cited the burdensome nature of the data collection as the primary reason for withdrawal. We also collected many exploratory outcomes that participants may have found onerous. Importantly, we would ensure that a follow-up trial decreases the questionnaire burden now that relevant parameters have been established. Moreover, if an in-person option is feasible, it may improve subject retention and satisfaction—though virtual sessions make future, larger treatment trials more scalable and enable delivery of the intervention to locations beyond major urban areas and academic centers.

The rationale for improvement of IBS-C symptoms with this multicomponent Tai Chi intervention is likely multifactorial, though the biologic mechanisms by which the intervention may work are largely theoretical. As a complex, multicomponent intervention, the mechanism of action may reflect effects on intermediate variables that ultimately improve overall health outcomes. IBS is recognized as a true biopsychosocial illness, where visceral hypersensitivity is modulated by a patient's psychosocial milieu. Thus, by improving psychological well-being, coping, and self-efficacy, Tai Chi mind-body may help patients with IBS engage in behaviors that help more effectively manage symptoms. Indeed, Tai Chi has been demonstrated to improve indicators of psychosocial well-being, with specific benefit on anxiety, depression, and stress. Indeed, Tai Chi has been demonstrated to maxiety, depression, and stress.

IBS is associated with abnormalities in autonomic nervous system function, ²⁶ with IBS-C specifically characterized by lower parasympathetic tone relative to IBS-D.²⁷ Tai Chi has been associated with enhanced vagal modulation, ^{28,29} which may preferentially benefit IBS-C patients. Sleep disturbances are also common in IBS, ³⁰ and Tai Chi has been associated with improvement in sleep quality in randomized, controlled trials.³¹ Thus, the benefits of Tai Chi in




FIGURE 3 Change in selected secondary measures over time; For leg strength, participants were asked to sit against a wall without support, legs bent at a 110 degree angle for as long as they could, at 80 percent of their maximum effort, using a self-timer. VAS, Visual Analog Scale

this population may occur across central and peripheral mechanisms, which is of specific benefit in a disease like IBS with such heterogeneous pathophysiology. Interestingly, the benefits seen with Tai

Chi occurred despite minimal impact on bowel movement frequency (CSBMs or SBMs), suggesting that symptom perception (particularly with pain and or bloating/distention) may have driven some of the

changes over time. Future investigations may benefit from formal measurement of autonomic function and sleep quality.

Our Tai Chi intervention was specifically designed with the abdominal complaints prevalent in IBS-C in mind. Abdominal bloating and distention are some of the most refractory symptoms in IBS-C relative to IBS-D with substantial impacts on quality of life. 32 Over time, participants experienced less bloating which continued over the 4 weeks after the intervention was completed. Importantly, this subjective improvement in bloating was accompanied by an objective decrease in abdominal circumference of 6.1 cm. Bloating and distention may be a potent driver of dietary restriction—both as a legitimate means of symptom avoidance and as disordered eating pathology.³³ In fact, food avoidance and restriction is a marker of IBS disease severity and reduced quality of life³⁴ that may be a marker of pathologic disordered eating, or avoidant restrictive food intake disorder (ARFID). 35-37 In our study, participants reported decreases in abdominal distention and decreased fear of foods and decreased avoidance and control behaviors related to food and eating, thus offering a unique potential treatment benefit of Tai Chi specifically that merits further investigation.

Despite the novelty of this trial, we acknowledge some limitations. Importantly, we saw a high attrition rate as described above, and the trial was not designed to assess efficacy. While the mixed model analysis avoids some sources of bias in the estimated symptom improvements, the study provides only proof-of-concept. In any trial of an intervention for IBS, the lack of a control arm is a significant limitation because of high placebo response rates in this population.³⁸ However, the changes in symptom severity remained stable 4 weeks after completing treatment, suggesting an ongoing benefit even after the intervention was complete. We did not elicit subject experience with Tai Chi or related practices during screening, which may have affected our results. Our study sample was also predominantly white, female, and skewed toward middle age. While this reflects the demographics of many IBS sample sets, this group may be more motivated to participate in a mind-body intervention. Interestingly, despite only 35% of individuals having had GI evaluation, symptoms were moderate in severity, suggesting that these types of interventions may be more acceptable to the large number of IBS patients who do not typically seek care.³⁹

In summary, we developed a novel Tai Chi program designed to meet the specific needs of patients suffering from IBS-C via live videoconferencing and tested its feasibility using a nonrandomized, proof-of-concept design. Our results show this novel mind-body intervention is both initially feasible and potentially effective and motivate a larger, randomized efficacy trial. Because IBS is a disease associated with substantial impacts on quality of life in the absence of mortality, ⁴⁰ focusing on interventions with patient acceptability is key. With the growing interest and acceptability of CAM treatments for chronic disease, further work is needed to create an evidence base for these therapies.

AUTHOR CONTRIBUTIONS

Kyle Staller, Ramel Rones, and Braden Kuo planned and designed the study; Mary Paz recruited participants and administered the study;

Isabelle Garcia-Fischer collected patient-specific data. Mary Paz, Helen Burton Murray, and Eric A. Macklin analyzed the data; Kyle Staller drafted the manuscript; all authors interpreted the results and contributed to critical review of the manuscript; Kyle Staller had full access to all of the data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis.

FUNDING INFORMATION

KS is supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) K23 DK120945. HBM is supported by NIDDKK23 DK131334.

DISCLOSURES

KS has received research support from Ironwood and Urovant and has served as a consultant to Arena, Gelesis, GI Supply, and Shire. BK has received research support from Medtronic, Gelesis, Takeda, Vanda, and consulting/speaking arrangements with Arena, CinDom, Cin Rx, Medtronic, Entrega, Ironwood, Neurogastrix, Phathom, Serepta, Sigma Wasserman, and Takeda. EAM has received research support via his institution from AI Therapeutics, Alector, Amylyx Pharmaceuticals, Biohaven Pharmaceuticals, Clene Nanomedicine, Mitsubishi Tanabe Pharmaceuticals America, Prilenia Neurotherapeutics, Revalesio, Seelos Therapeutics, and UCB Ra Pharma and has served on steering committees for Biogen and Stoparkinson Healthcare Systems, on advisory boards for Alector, Bial Therapeutics, Cerevance, Cortexyme, Enterin, Intrance Medical, nQ Medical, Partner Therapeutics, and on data monitoring committees for Novartis and Sanofi.

ORCID

Kyle Staller https://orcid.org/0000-0003-4925-4290

Helen Burton Murray https://orcid.org/0000-0003-2059-3256

REFERENCES

- Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712-21.e4.
- Rangan V, Ballou S, Shin A, Camilleri M, Beth Israel Deaconess Medical Center GIMWG, Lembo A. Use of treatments for irritable bowel syndrome and patient satisfaction based on the IBS in America Survey. Gastroenterology. 2020;158(3):786-8.e1.
- 3. Dossett ML, Davis RB, Lembo AJ, Yeh GY. Complementary and alternative medicine use by US adults with gastrointestinal conditions: results from the 2012 National Health Interview Survey. *Am J Gastroenterol.* 2014;109(11):1705-1711.
- Nguyen L. Complementary and alternative medicine for the management of irritable bowel syndrome. Gastroenterol Hepatol. 2018:14(9):536-538.
- Wayne PM, Kaptchuk TJ. Challenges inherent to t'ai chi research: part I-t'ai chi as a complex multicomponent intervention. J Altern Complement Med. 2008;14(1):95-102.
- Wang C, Schmid CH, Rones R, et al. A randomized trial of Tai Chi for fibromyalgia. N Engl J Med. 2010;363(8):743-754.
- Jones KD, Sherman CA, Mist SD, Carson JW, Bennett RM, Li F. A randomized controlled trial of 8-form Tai Chi improves symptoms and functional mobility in fibromyalgia patients. *Clin Rheumatol*. 2012;31(8):1205-1214.

- Wang C, Schmid CH, Fielding RA, et al. Effect of Tai Chi versus aerobic exercise for fibromyalgia: comparative effectiveness randomized controlled trial. BMJ. 2018;360:k851.
- Sperber AD, Atzmon Y, Neumann L, et al. Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. Am J Gastroenterol. 1999:94(12):3541-3546.
- Wang F, Lee EK, Wu T, et al. The effects of Tai Chi on depression, anxiety, and psychological well-being: a systematic review and meta-analysis. Int J Behav Med. 2014;21(4):605-617.
- Johannesson E, Simren M, Strid H, Bajor A, Sadik R. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol. 2011;106(5):915-922.
- 12. Zhou C, Zhao E, Li Y, Jia Y, Li F. Exercise therapy of patients with irritable bowel syndrome: a systematic review of randomized controlled trials. *Neurogastroenterol Motil.* 2019;31(2):e13461.
- 13. Palsson OS, Baggish JS, Turner MJ, Whitehead WE. IBS patients show frequent fluctuations between loose/watery and hard/lumpy stools: implications for treatment. *Am J Gastroenterol*. 2012;107(2):286-295.
- Czajkowski SM, Powell LH, Adler N, et al. From ideas to efficacy: the ORBIT model for developing behavioral treatments for chronic diseases. *Health Psychol.* 2015;34(10):971-982.
- 15. Mearin F, Lacy BE, Chang L, et al. Bowel Disorders. *Gastroenterology*. 2016;150(6):1393-1407.
- Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. *Aliment Pharmacol Ther*. 1997;11(2):395-402.
- 17. Lembo AJ, Conboy L, Kelley JM, et al. A treatment trial of acupuncture in IBS patients. *Am J Gastroenterol*. 2009;104(6):1489-1497.
- Svedlund J, Sjodin I, Dotevall G. GSRS--a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. *Dig Dis Sci.* 1988;33(2):129-134.
- Drossman D, Morris CB, Hu Y, et al. Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment. Am J Gastroenterol. 2007;102(7):1442-1453.
- Labus JS, Bolus R, Chang L, et al. The Visceral Sensitivity Index: development and validation of a gastrointestinal symptom-specific anxiety scale. *Aliment Pharmacol Ther.* 2004;20(1):89-97.
- Reme SE, Darnley S, Kennedy T, Chalder T. The development of the irritable bowel syndrome-behavioral responses questionnaire. J Psychosom Res. 2010;69(3):319-325.
- 22. Hunt M, Zickgraf H, Gibbons B, Loftus P. Development and Validation of the Fear of Food Questionnaire (FFQ). Poster presented at the annual meeting of the Anxiety and Depression Association of America; 2018; Washington D.C.
- Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983:67(6):361-370.
- Wang C, Schmid CH, Iversen MD, et al. Comparative effectiveness of Tai Chi versus physical therapy for knee osteoarthritis: a randomized trial. Ann Intern Med. 2016;165(2):77-86.
- Wang C, Bannuru R, Ramel J, Kupelnick B, Scott T, Schmid CH. Tai Chi on psychological well-being: systematic review and metaanalysis. BMC Complement Altern Med. 2010;10:23.
- 26. Aggarwal A, Cutts TF, Abell TL, et al. Predominant symptoms in irritable bowel syndrome correlate with specific autonomic nervous system abnormalities. *Gastroenterology*. 1994;106(4):945-950.
- Heitkemper M, Jarrett M, Cain KC, et al. Autonomic nervous system function in women with irritable bowel syndrome. *Dig Dis Sci*. 2001;46(6):1276-1284.

- Lu WA, Kuo CD. The effect of Tai Chi Chuan on the autonomic nervous modulation in older persons. *Med Sci Sports Exerc*. 2003;35(12):1972-1976.
- Lu WA, Kuo CD. Breathing frequency-independent effect of Tai Chi Chuan on autonomic modulation. Clin Auton Res. 2014;24(2):47-52.
- Tu Q, Heitkemper MM, Jarrett ME, Buchanan DT. Sleep disturbances in irritable bowel syndrome: a systematic review. Neurogastroenterol Motil. 2017;29(3):e12946.
- Si Y, Wang C, Yin H, et al. Tai Chi Chuan for subjective sleep quality: a systematic review and meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med. 2020;2020;4710527.
- 32. Lacy BE, Cangemi D, Vazquez-Roque M. Management of chronic abdominal distension and bloating. *Clin Gastroenterol Hepatol*. 2021;19(2):219-31.e1.
- Werlang ME, Sim LA, Lebow JR, Lacy BE. Assessing for eating disorders: a primer for gastroenterologists. Am J Gastroenterol. 2021:116(1):68-76.
- 34. Melchior C, Algera J, Colomier E, Tornblom H, Simren M, Storsrud S. Food avoidance and restriction in irritable bowel syndrome: relevance for symptoms, quality of life and nutrient intake. *Clin Gastroenterol Hepatol.* 2022;20(6):1290-1298.e4.
- Murray HB, Staller K. When food moves from friend to foe: why avoidant/restrictive food intake matters in irritable bowel syndrome. Clin Gastroenterol Hepatol. 2022;20(6):1223-1225.
- Burton Murray H, Riddle M, Rao F, et al. Eating disorder symptoms, including avoidant/restrictive food intake disorder, in patients with disorders of gut-brain interaction. *Neurogastroenterol Motil*. 2021;e14258.
- Murray HB, Bailey AP, Keshishian AC, et al. Prevalence and characteristics of avoidant/restrictive food intake disorder in adult neurogastroenterology patients. Clin Gastroenterol Hepatol. 2020;18(9):1995-2002.e1.
- Ballou S, Beath A, Kaptchuk TJ, et al. Factors associated with response to placebo in patients with irritable bowel syndrome and constipation. Clin Gastroenterol Hepatol. 2018;16(11):1738-44.e1.
- 39. Camilleri M. diagnosis and treatment of irritable bowel syndrome: a review. *JAMA*. 2021;325(9):865-877.
- 40. Staller K, Olen O, Soderling J, et al. Mortality risk in irritable bowel syndrome: results from a nationwide prospective cohort study. *Am J Gastroenterol.* 2020;115(5):746-755.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Staller K, Paz M, Rones R, et al. Virtual Tai Chi program for patients with irritable bowel syndrome with constipation: Proof-of-concept feasibility trial. *Neurogastroenterology & Motility*. 2022;00:e14429. doi: 10.1111/nmo.14429